SAB Biotherapeutics (SABS) Stock: Buy, Sell, or Hold?
SABS - SAB Biotherapeutics, Inc. Common Stock
$2.84
-0.20 (-6.58%)
▼
5d:
+12.25%
30d:
-15.22%
90d:
-17.44%
BUY
HIGH Confidence
Analysis Updated: Oct 22, 2026 12:00 AM ET
Earnings: Nov 13, 2026
20d
Get Alerted When SABS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: SABS shows strong fundamentals and good volume confirmation. Solid entry point despite slightly low pricing.
✅ BUY SIGNAL: SABS shows strong fundamentals and good volume confirmation. Solid entry point despite slightly low pricing.
In-depth Analysis How we analyze
Valuation Analysis: SABS is currently trading at $2.84, which is considered slightly low relative to its 30-day fair value range of $2.76 to $3.37.
Technical Outlook: Technically, SABS is in a downtrend. Immediate support is located at $2.44, while resistance sits at $3.08. Short-term momentum is weak, with the stock down 6.6% recently.
Market Sentiment: SABS scores 70/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $11.64 (+309.7%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, SABS is in a downtrend. Immediate support is located at $2.44, while resistance sits at $3.08. Short-term momentum is weak, with the stock down 6.6% recently.
Market Sentiment: SABS scores 70/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $11.64 (+309.7%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$2.76 -
$3.37
Company Quality Score
54/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
89.5%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Strong technical setup (70/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-6.6%)
- BULLISH: Trading 309.7% below Wall St target ($11.64)
- BULLISH: Bottoming setup score 70/100 — corrected, stabilizing, and turning up
Trading Range Analysis
30-Day Trading Range
$2.76 -
$3.37
Current vs Trading Range
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$2.44
Resistance Level
$3.08
Current Trend
Downtrend
Technical data as of
Oct 23, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-2.98
Wall Street Target
$11.64
(+309.7%)
Revenue Growth (YoY)
-62.4%
Earnings Growth (YoY)
-60.0%
Share & Embed Analysis
Last updated: October 23, 2026 6:07 PM ET
Data refreshes hourly during market hours. Next update: 7:07 PM
Data refreshes hourly during market hours. Next update: 7:07 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is SABS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
VRTX
Vertex Pharmaceuticals I… |
STRONG BUY
32 analysts |
$571 | 58 HOLD |
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
30 analysts |
$369 | 52 HOLD |
|
ONC
BeiGene, Ltd. |
STRONG BUY
27 analysts |
$436 | 38 SELL |
|
ASND
Ascendis Pharma AS |
STRONG BUY
21 analysts |
$307 | 51 HOLD |
|
RYTM
Rhythm Pharmaceuticals I… |
STRONG BUY
18 analysts |
$144 | 75 BUY |
